Eleazar Sukenik

Electric Symphony Media Honored as a Finalist in 2022 The Drum Digital Advertising Awards

Retrieved on: 
Monday, April 11, 2022
Friends, Organization, American Friends of the Hebrew University, Investment, Retention, KPI, Advertising, Magnetic Drum Digital Differential Analyzer, Research, Diplomacy, Medicine, American Friends, Health, KPI-driven code analysis, Eleazar Sukenik, Hebrew University of Jerusalem, Digital, Technology, Knowledge, COVID-19, Goal, ESM, Autumn, Science, Education, AFHU, Social media, Public relations, Pharmaceutical industry, Sales, Risk management, Acquisition

HOBOKEN, N.J., April 11, 2022 /PRNewswire-PRWeb/ -- The Drum Digital Advertising Awards is a global awards program that recognizes the best technology and digital media in advertising. With 38 total categories, ESM entered the Not-for-Profit/Charity category, for work with nonprofit organization, AFHU, and we were shortlisted among two other top agency contenders. Winners are set to be announced on April 21, 2022.

Key Points: 
  • Electric Symphony Media is recognized by The Drum Digital Advertising Awards as a finalist in the category of Not-for-Profit/Charity Category for our work with American Friends of the Hebrew University.
  • HOBOKEN, N.J., April 11, 2022 /PRNewswire-PRWeb/ -- The Drum Digital Advertising Awards is a global awards program that recognizes the best technology and digital media in advertising.
  • ESM is honored to have our work recognized alongside global agencies and businesses.
  • As a boutique firm, we pride ourselves on creating innovative and effective media campaigns that are just as competitive as much larger organizationswithout the red tape.

Cytovia Therapeutics’ Leadership to Present at Upcoming Conferences

Retrieved on: 
Tuesday, March 29, 2022
Cornerstone, Therapy, Glioblastoma, UCSF, Cellectis, Research, INSERM, Conference, Hepatocellular carcinoma, Cancer, Lymphatic system, Laboratory, Hebrew University of Jerusalem, Eleazar Sukenik, Technology, University of California, San Francisco, GLOBE, HCC, Ink, GMP, University, Patient, Partnership, Vaccine, Pharmaceutical industry, NCR1

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.

Key Points: 
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms.
  • Headquartered in Aventura, Fla., Cytovia has research and development laboratories in Natick, Mass., and a GMP cell manufacturing facility in Puerto Rico.
  • Cytovia has recently formed CytoLynx Therapeutics, a partnership focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

The Automotive Hall Of Fame Announces 2022 Mobility Innovator Award

Retrieved on: 
Thursday, March 31, 2022
AVS, Automotive Hall of Fame, Bank of Israel, Awards ceremony, 2007 College Football Hall of Fame inductees, CEO, Language, Intelligence, Eleazar Sukenik, Senior, Hebrew University of Jerusalem, Artificial intelligence, Industry, Safety, AHF, Bank, The Icon, Machine learning, Hall, Algorithm, 2011 National Soccer Hall of Fame Induction Class, Intel, Facebook, ADAS, Mobility, Efficiency, IPO, Instagram, AI, Acquisition, MI, Management, Online gambling, Satellite navigation device, Mobile phone, Fame, Mobileye, Amnon Shashua

DEARBORN, Mich., March 31, 2022 /PRNewswire-PRWeb/ -- Today the Automotive Hall of Fame announced its 2022 Mobility Innovator Awardee – Prof. Amnon Shashua, President and CEO of Mobileye. Introduced last year, this noteworthy award recognizes the outstanding work individuals have accomplished introducing new technologies and services that are redefining mobility.

Key Points: 
  • Automotive Hall of Fame names Amnon Shashua, President and CEO of Mobileye, as 2022 Mobility Innovator Award recipient.
  • DEARBORN, Mich., March 31, 2022 /PRNewswire-PRWeb/ -- Today the Automotive Hall of Fame announced its 2022 Mobility Innovator Awardee Prof. Amnon Shashua, President and CEO of Mobileye.
  • The Mobility Innovator Award celebrates individuals and their impact," said Sarah Cook, president of the Automotive Hall of Fame.
  • Shashua will be recognized along with the 2022 Automotive Hall of Fame Inductees (previously announced) at the Automotive Hall of Fame Induction and Awards Ceremony held on Thursday, July 21, 2022, at The Icon (200 Walker St. Detroit, MI).

Chainlink Labs Announces Key Executive Hires

Retrieved on: 
Tuesday, March 29, 2022
Adoption, Diem (digital currency), LinkedIn, Microsoft Research, Blockchain, API, Growth, Multimedia, Thomson Reuters, Publication, Research, Reading, Chain-link fencing, CEO, CTO, Mathematics, Solution, Hebrew University of Jerusalem, Eleazar Sukenik, Association, Technology, Novi, IOT, Accelerated Learning Solutions, SAN, Cryptocurrency, Dahlia, Web3

SAN FRANCISCO , March 29, 2022 /PRNewswire/ -- Chainlink Labs, the organization developing the global decentralized oracle standard powering mainstream blockchain adoption, today announced that Dr. Dahlia Malkhi, former Diem Association chief technology officer, has joined as chief research officer. Dr. Malkhi joins other recent new executive team hires, including Mike Derezin, former vice president at LinkedIn, who joined late last year as chief operating officer.

Key Points: 
  • Dr. Malkhi joins other recent new executive team hires, including Mike Derezin, former vice president at LinkedIn, who joined late last year as chief operating officer.
  • Dr. Malkhi joins Chainlink Labs from the Diem Association, where she was CTO and lead maintainer, as well as lead researcher at Novi.
  • I'm looking forward to expanding the in-house innovation capabilities at Chainlink Labs, leveraging our existing technology advantage as a springboard to solidify Chainlink offerings as the industry standard for trust-minimized blockchain services."
  • Derezin will provide the operational excellence that enables the continued growth and success of Chainlink Labs.

Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors

Retrieved on: 
Monday, March 21, 2022
Company, NASDAQ, Boston University, Montgomery, Chairperson, Ruti, Board, Alpha Sigma Tau, Physician, MACA, Kidder, Peabody & Co., Research, Montgomery Securities, Neoplasm, CEO, Economics, Board of directors, Hebrew University of Jerusalem, Eleazar Sukenik, LLC, Technology, Industry, Knowledge, Goal, Alpha, Nasdaq, Surgeon, R, IATI, Columbia University School of General Studies, Patient, Pharmaceutical industry, Pitango, Tel Aviv University

JERUSALEM, March 21, 2022 /PRNewswire/ --Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately.

Key Points: 
  • JERUSALEM, March 21, 2022 /PRNewswire/ --Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately.
  • "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau.
  • Ruti Alon added, "I have been following Alpha Tau from its inception, always believing in the technology and its potential.
  • Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors.

Cytovia Therapeutics to Present Preclinical Data for iPSC-derived NK Cells and Flex-NK™ Engager Multispecific Antibodies at 2022 AACR Annual Meeting

Retrieved on: 
Wednesday, March 16, 2022
Association, Cornerstone, Therapy, American Association for Cancer Research, Multiple myeloma, Abstract (summary), Technology, University, GMP, GLOBE, Hebrew University of Jerusalem, Patient, Partnership, AACR, Ink, GPC3, NK, HCC, Eleazar Sukenik, American Association, Glioblastoma, Lymphatic system, Annual general meeting, Neoplasm, Cellectis, Cell, Research, Cancer, CD38, CEO, University of California, San Francisco, UCSF, INSERM, Hepatocellular carcinoma, Laboratory, Vaccine, NCR1

Cytovia is the first immune-oncology company to present data combining its own iPSC-derived NK cells and NK engager antibodies for the treatment of solid tumors.

Key Points: 
  • Cytovia is the first immune-oncology company to present data combining its own iPSC-derived NK cells and NK engager antibodies for the treatment of solid tumors.
  • Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer.
  • Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive NK-cell and NK-engager antibody platforms.
  • Cytovia has recently formed CytoLynx Therapeutics, a partnership focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

Vaica Strengthens leadership team with a new CMO- Prof. Oz Shapira

Retrieved on: 
Tuesday, March 15, 2022
Eleazar Sukenik, Hebrew University of Jerusalem, Telehealth, Knowledge, TEL, RTM, Remote patient monitoring, RPM, Medicine, CEO, Hadassah Medical Center, Medical device

Oz Shapira is a Professor of Cardiothoracic Surgery at the Hebrew University, Hadassah Medical School, Jerusalem, Israel.

Key Points: 
  • Oz Shapira is a Professor of Cardiothoracic Surgery at the Hebrew University, Hadassah Medical School, Jerusalem, Israel.
  • Prof. Shapira has nearly 40 years of clinical experience along-with nearly 25-years of experience in senior leadership positions.
  • "We are honored to have Oz as part of our leadership team."
  • Vaica is a telemedicine company bringing together Remote Patient Management (RPM), and Remote Therapeutic Management (RTM), tracking the patient's vitals, medication adherence and persistence.

Stav Gaon Joins Academy Securities as Head of Securitized Products Research and Strategy

Retrieved on: 
Monday, February 28, 2022
Banking, Professional Services, Finance, ESG, Leadership, Faculty, SDVOSB, Head, Hebrew University of Jerusalem, Security (finance), MBE, Columbia Business School, Research, LL.B, Minority business enterprise, Eleazar Sukenik, CUHK Faculty of Law, Business, Central University of Finance and Economics, Citigroup, CMBS, School of Economics and Business, Ljubljana, CEO, Doctor of Philosophy, Financial services, Management, Academy, Economics

Academy Securities, a registered broker-dealer, certified Disabled Veteran Business Enterprise (DVBE), and Minority Business Enterprise (MBE), today announced the addition of Stav Gaon as Head of Securitized Products Research and Strategy.

Key Points: 
  • Academy Securities, a registered broker-dealer, certified Disabled Veteran Business Enterprise (DVBE), and Minority Business Enterprise (MBE), today announced the addition of Stav Gaon as Head of Securitized Products Research and Strategy.
  • Dr. Gaon joins Academy after a 16-year career at Citigroup where he worked as Co-Head of Global Securitized Products CMBS and CRE Strategy.
  • Dr. Gaon commented on joining Academy Securities: I am very excited and honored to join Academy Securities.
  • I look forward to building and growing Academys securitized products research platform, and to providing insights that hopefully add value to Academy clients as they make their investment decisions.

Andrei Damian, M.D., F.A.C.C is recognized by Continental Who's Who

Retrieved on: 
Tuesday, February 15, 2022
Patient, IRMS, Medicine, Education, American College, Eleazar Sukenik, American College of Cardiology, Hebrew University of Jerusalem, Hospital, Acquisition, CVC, FACC, Multimedia, Continental, Online shopping, Phoenix

He has years of experience creating healthcare models that benefit the consumer and allow them to pay less for high-quality medical care.

Key Points: 
  • He has years of experience creating healthcare models that benefit the consumer and allow them to pay less for high-quality medical care.
  • Dr. Damian has expertise in creating value-added contracts and collaborating on healthcare models.
  • To obtain his education, Dr. Damian attended the Hebrew University of Jerusalem, where he earned a Doctor of Medicine degree.
  • Dr. Damian built Lifeprint Healthcare in 2000 from scratch to create private equity based outpatient services.

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

Retrieved on: 
Monday, January 31, 2022
Growth, Finger, Private Securities Litigation Reform Act, Risk, Eleazar Sukenik, Medication, Inflammation, Fed, Patient, Budget, PALO, Health care, Anomaly, NASDAQ, Food, SEC, Behavior, IP, Depression, Form, Contracture, COVID, Hardness, Research, Nasdaq, MHRA, US Foods, Disease, Program, POCD, Hebrew University of Jerusalem, U.S. Securities and Exchange Commission, EU, Fibrosis, University of Oxford, Injection, List of life sciences, IR, Company, Stanford University, ATNF, Manuscript, GLOBE, Letter, Pain, Time, Fear, Comment, FDA, Therapy, Security (finance), Disability, TNF, Adalimumab, Pharmaceutical industry, Public relations, Fine chemical

As you may recall, I previously authored a letter to you at the end of August 2021.

Key Points: 
  • As you may recall, I previously authored a letter to you at the end of August 2021.
  • I continue to believe ongoing communications with our shareholders is a foundational responsibility of being a public company.
  • The Companys fundamentals have not changed since our release of positive clinical data in early December 2021, as discussed below.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.